Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide and Concomitant Medicines

A Danish register study found shifts in several prescribing categories after semaglutide initiation, but it cannot establish causation.

Why we wrote this. Large prescribing-data studies can be misread as medication advice, so this article separates observed patterns from causal and individual conclusions.

In this article (5 sections)
  1. What the researchers studied
  2. Changes reported at 12 months
  3. Why interrupted time-series results need context
  4. What the study does not establish
  5. A careful takeaway

A nationwide Danish interrupted time-series study examined medicine dispensing before and after people started semaglutide for weight management. It found changes in several categories of concomitant medicines, including a slower-than-projected rise in antihypertensive prescriptions and an increase in anxiolytic use. These are prescribing-pattern associations. They do not show that semaglutide caused each change or that a person should alter any treatment[1].

What the researchers studied

The study used Danish registers and included adults starting semaglutide for weight management between December 2022 and December 2024. It analyzed monthly prescriptions in ten medication classes across the 24 months before initiation and 12 months after. The researchers estimated 12-month effects as rate ratios comparing observed dispensing with levels projected from pre-initiation trends[1]. The Crossref record identifies the report in Diabetes, Obesity and Metabolism[2].

This design asks whether prescribing changed relative to each class's earlier trajectory, but it does not randomly assign semaglutide. It therefore cannot eliminate changes in healthcare use, prescribing practice, illness severity, or other factors that may happen around the same time. The authors' results are best read as signals for further study rather than a guide to changing concurrent medicines.

Changes reported at 12 months

Among 189,392 initiators, the abstract reports lower-than-projected prescription volumes for antiasthmatics, topical corticosteroids, antipsoriatics, analgesics, antidepressants, and topical antifungal preparations. Antihypertensive dispensing continued to rise, but less quickly than the projected trend. These measures concern filled prescriptions in registers. They do not directly measure symptoms, disease control, or whether a medicine was clinically necessary[1].

Glucose-lowering medicine dispensing also declined in the analysis, mainly among non-insulin medicines. However, the abstract says a similar reduction appeared in the negative-control cohort. That observation limits a simple interpretation that semaglutide alone explains the change. The study instead supplies a careful prompt to examine prescribing patterns with suitable comparison groups[1].

Anxiolytic use increased, with a reported 12-month rate ratio of 1.16 and persistence at two years. This deserves attention, but it is not proof of a drug effect. Register data cannot by themselves establish the clinical reason for a prescription or separate potential treatment effects from circumstances that influence both medicine use and weight-management care[1].

Why interrupted time-series results need context

Interrupted time-series analysis is useful when researchers want to compare observed patterns with prior trends. Its strength is the explicit pre-initiation reference period. Its limitation is that many exposures can change at once. A shift after initiation may reflect the medicine, clinical review, lifestyle support, policy, supply, or a broader change in patient care. The study cannot sort every explanation without more evidence.

The population was drawn from Danish registers, and 68% of the initiators were women with a median age of 50 years. Results from that system should not be assumed to apply unchanged to other countries or patient populations. Our semaglutide evidence page offers separate context about the medicine's studied effects.

What the study does not establish

The paper does not establish that semaglutide lets patients stop blood-pressure, mental-health, pain, or other medicines. It reports dispensing patterns. Any decision to start, stop, or adjust a prescribed medicine requires the clinician responsible for that treatment. A medication list can reflect multiple conditions, and a register-based pattern cannot decide what is appropriate for a particular person.

Nor does the study establish that increased anxiolytic dispensing is an adverse effect of semaglutide. The authors call for continued monitoring of prescribing patterns during treatment, which is not the same as demonstrating a cause. Readers can review semaglutide safety context and clinical evidence context for distinct evidence questions.

The data cannot answer every practical question. A prescription being filled does not confirm that a person took it, why the clinician chose it, or how the person responded. Conversely, an unchanged prescription does not prove that a condition did not change. Register data are powerful for scale, but they are not a substitute for records that capture clinical reasoning and patient experience.

The negative-control finding is especially important. When a similar change occurs in people outside the focal exposure group, it can point to a secular trend or another shared influence. That does not erase the observed semaglutide pattern. It makes the causal explanation less certain. Readers can use the semaglutide overview and regulation context to keep medication status separate from observational findings.

The study also has no instruction for patients. It does not say which people should reduce treatment, which medicine class should be favored, or how symptoms should be monitored. That restraint is appropriate. Medical decisions require information that does not appear in an interrupted time series, including diagnoses, laboratory findings, examination, and the goals of care. The safety evidence page, trial evidence page, and semaglutide reference page address other questions without replacing a clinical review.

A careful takeaway

This large register study documents changes in concurrent prescribing after semaglutide initiation for weight management. It is valuable for identifying questions that need direct testing. It is not a medication-reduction protocol or personal medical advice. This article is educational and is not medical advice. Anyone concerned about symptoms or medicines should speak with a qualified clinician rather than changing treatment based on a population-level association.

Frequently asked

What was the study's design?

It was a nationwide interrupted time-series study using Danish register data and comparing observed dispensing with pre-initiation trends.

Did it show people can stop other medicines?

No. It measured dispensing patterns and does not determine whether any individual should start, stop, or adjust treatment.

Does increased anxiolytic use prove a semaglutide effect?

No. The association requires further study because register data cannot establish the reason for a prescription or causation.

What should patients do with these results?

Use them as context for discussion, not as medical instructions. Medication decisions should be made with the clinician responsible for care.

Sources

  1. [1]Impact of Semaglutide Introduction on Concomitant Medication Use: interrupted time series. PMID 42928048.Tier 1 · primary↩
  2. [2]Crossref record for DOI 10.1111/dom.71489.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars